--- title: "FOX04-DRI Peptide UK - Compare Prices from 26 Suppliers - PeptideSupermarket®" description: "Compare FOX04-DRI prices from 26 UK suppliers, from £25.00. Find the cheapest deals, read reviews and save money." url: "https://peptidesupermarket.co.uk/peptide/fox04-dri" site: "PeptideSupermarket®" country: "United Kingdom" --- [Home](https://peptidesupermarket.co.uk) › [Peptides](https://peptidesupermarket.co.uk/compare-peptide-prices-uk) › FOX04-DRI Search # FOX04-DRI Price Comparison Live prices from 26 UK suppliers, from £25.00, compared side by side so you never overpay. [Skin & cellular longevity research](https://peptidesupermarket.co.uk/compare-peptide-prices-uk) Prices checked 4 hours ago We compare prices & may earn a commission. Includes a featured placement — not an endorsement. [Full disclosure](https://peptidesupermarket.co.uk/disclosure). Best Price £25.00 Average £123.62 Highest £526.40 You Could Save 95% 26 results 10mg Featured Supplier [Kensington Labs](https://peptidesupermarket.co.uk/suppliers/kensington-labs) FOX04-DRI In Stock 10mg Lab Tested 50 Confidence £169.90 FREE delivery View Deal Compare 26 prices for FOX04-DRI. Cheapest: £25.00. Average: £123.62. | Compare | Supplier | Price | Price / mg | Stock | Delivery | Quality | Coupon | Visit | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 95 Confidence [Ultra Peptides](https://peptidesupermarket.co.uk/suppliers/ultra-peptides-uk) ★★★★★ 5.0 (13) FOX04-DRI 10mg | £69.99 | £7.00/mg | In Stock | Free | Lab Tested | — | Visit | | | 95 Confidence [BioPlex Peptides](https://peptidesupermarket.co.uk/suppliers/bioplex-peptides) ★★★★★ 5.0 (1) FOX04-DRI 10mg | £78.99 | £7.90/mg | In Stock | Free | Lab Tested | — | Visit | | | 95 Confidence [Midshire Labs](https://peptidesupermarket.co.uk/suppliers/midshire-labs) FOX04-DRI | £74.00 | £7.40/mg | In Stock | Free over £50 | Lab Tested | — | Visit | | | 80 Confidence [Raccoon Peptides](https://peptidesupermarket.co.uk/suppliers/raccoon-peptides) ★★★★★ 5.0 (1) FOX04-DRI | £49.50 | £4.95/mg | In Stock | Free | Lab Tested | — | Unavailable | | | 80 Confidence [Raccoon Peptides](https://peptidesupermarket.co.uk/suppliers/raccoon-peptides) ★★★★★ 5.0 (1) FOX04-DRI Pen | £104.00 | £10.40/mg | In Stock | Free | Lab Tested | — | Unavailable | | | 70 Confidence [RC Peptides](https://peptidesupermarket.co.uk/suppliers/rc-peptides) ★★★★★ 4.8 (176) FOX04-DRI | £50.00 | £5.00/mg | In Stock | Free | Lab Tested | — | Visit | | | 68 Confidence [Woodlands Biohack](https://peptidesupermarket.co.uk/suppliers/woodlands-biohack) FOX04-DRI 10mg | £526.40 | £52.64/mg | In Stock | Free over £100 | Lab Tested | — | Visit | | | 64 Confidence [Union Biolabs](https://peptidesupermarket.co.uk/suppliers/union-biolabs) FOX04-DRI 10mg | £85.00 | £8.50/mg | In Stock | Free | Lab Tested | — | Visit | | | 50 Confidence [XL Peptides](https://peptidesupermarket.co.uk/suppliers/xl-peptides) ★★★★★ 5.0 (1) FOX04-DRI | £45.00 | £4.50/mg | In Stock | Free | Lab Tested | — | Visit | | | 50 Confidence [Genopept](https://peptidesupermarket.co.uk/suppliers/genopept) Best FOX04-DRI 10mg | £25.00 | £2.50/mg | Low Stock | Free over £200 | Lab Tested | — | Visit | | | 50 Confidence [NI Peptides](https://peptidesupermarket.co.uk/suppliers/ni-peptides) FOX04-DRI 10mg | £65.00 | £6.50/mg | In Stock | £9.99 | — | — | Visit | | | 50 Confidence [OP Labs](https://peptidesupermarket.co.uk/suppliers/op-labs) FOX04_DRI 10mg | £69.99 | £7.00/mg | In Stock | Free | Lab Tested | — | Visit | | | 50 Confidence [Nexum Peptides](https://peptidesupermarket.co.uk/suppliers/nexum-peptides) FOX04-DRI 10mg | £69.99 | £7.00/mg | In Stock | Free | Lab Tested | — | Visit | | | 50 Confidence [Bionik Peptides](https://peptidesupermarket.co.uk/suppliers/bionik-peptides) FOX04-DRI 10mg | £70.00 | £7.00/mg | In Stock | Free | — | — | Visit | | | 50 Confidence [NASS Peptides](https://peptidesupermarket.co.uk/suppliers/nass-peptides) FOX04-DRI 10mg | £73.50 | £7.35/mg | In Stock | Free | Lab Tested | — | Unavailable | | | 50 Confidence [Anglo Peptides](https://peptidesupermarket.co.uk/suppliers/anglo-peptides) FOX04-DRI | £85.00 | £8.50/mg | In Stock | Free over £100 | Lab Tested | — | Visit | | | 50 Confidence [Performance Peptides UK](https://peptidesupermarket.co.uk/suppliers/performance-peptides-uk) FOX04-DRI 10mg | £85.00 | £8.50/mg | In Stock | £9.99 | — | — | Visit | | | 50 Confidence [Optimal Lab](https://peptidesupermarket.co.uk/suppliers/optimal-lab) FOX04-DRI 10mg | £95.00 | £9.50/mg | In Stock | £9.99 | — | — | Visit | | | 50 Confidence [Biolabs](https://peptidesupermarket.co.uk/suppliers/biolabs) FOX04-DRI 10mg | £172.22 | £17.22/mg | In Stock | Free | — | — | Visit | | | 50 Confidence [Biolabshopuk](https://peptidesupermarket.co.uk/suppliers/biolabshopuk) FOX04-DRI 10mg | £174.99 | £17.50/mg | In Stock | Free | — | — | Unavailable | | | 50 Confidence [Biolabshopofficial](https://peptidesupermarket.co.uk/suppliers/biolabshopofficial) FOX04-DRI 10mg | £174.99 | £17.50/mg | In Stock | Free | — | — | Unavailable | | | 50 Confidence [Orbitrex Peptides](https://peptidesupermarket.co.uk/suppliers/orbitrex-peptides) FOX04-DRI 10mg | £189.99 | £19.00/mg | In Stock | Free | Lab Tested | — | Visit | | | 50 Confidence [Syntech](https://peptidesupermarket.co.uk/suppliers/syntech) FOX04-DRI 10mg | £189.99 | £19.00/mg | In Stock | Free | Lab Tested | — | Visit | | | 50 Confidence [Direct Peptides](https://peptidesupermarket.co.uk/suppliers/direct-peptides) FOX04-DRI 10mg | £197.40 | £19.74/mg | In Stock | Free | Lab Tested | — | Visit | | | 50 Confidence [Peptide House](https://peptidesupermarket.co.uk/suppliers/peptide-house) FOX04-DRI 10mg | £223.25 | £22.33/mg | In Stock | £9.99 | — | — | Unavailable | More ways to compare FOX04-DRI Different views of the same live UK pricing, tuned for how you like to shop. [Best FOX04-DRI Prices Best prices ranked](https://peptidesupermarket.co.uk/best-fox04-dri-prices) [Cheapest FOX04-DRI Prices Cheapest suppliers compared](https://peptidesupermarket.co.uk/cheapest-fox04-dri-prices) [Where to Buy FOX04-DRI Full buyer's guide](https://peptidesupermarket.co.uk/where-to-buy-fox04-dri) [Buy FOX04-DRI Online UK Cheap Today's hottest deals](https://peptidesupermarket.co.uk/buy-fox04-dri-online-uk-cheap) [FOX04-DRI Price Comparison Live price dashboard](https://peptidesupermarket.co.uk/fox04-dri-price-comparison) [FOX04-DRI UK Supplier Verified UK supplier directory](https://peptidesupermarket.co.uk/fox04-dri-uk-supplier) [FOX04-DRI For Sale Browse listings for sale](https://peptidesupermarket.co.uk/fox04-dri-for-sale) Compare another peptide Search PeptideSupermarket® compares prices but doesn't sell products. More All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed. We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed. By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. [Read our full disclosure](https://peptidesupermarket.co.uk/disclosure). ## FOX04-DRI Profile Preclinical FOXO4‑DRI | D‑retro‑inverso peptide senolytic (FOXO4–p53 interaction inhibitor) ### Overview FOXO4‑DRI is a D‑retro‑inverso peptide designed to disrupt the interaction between FOXO4 and p53, a complex that helps senescent cells resist apoptosis. In mouse and cell culture studies, this selective disruption can trigger apoptosis predominantly in senescent cells while sparing non‑senescent counterparts, making FOXO4‑DRI a widely used tool compound in senescence biology. ### Mechanism of Action In senescent cells, FOXO4 physically interacts with p53 (notably via the FOXO4 CR3 domain), tethering p53 in the nucleus and promoting a pro‑survival state. FOXO4‑DRI is a D‑retro‑inverso analog of the FOXO4 CR3 peptide (often coupled to a cell‑penetrating sequence) that competitively binds p53, displacing endogenous FOXO4. This releases p53 from the FOXO4 scaffold, promoting p53‑dependent apoptosis selectively in senescent cells where FOXO4–p53 engagement is elevated, thereby reducing senescence‑associated secretory phenotype (SASP) signaling and senescent cell burden in preclinical models. ### Key Benefits - Selective induction of apoptosis in senescent cells in vitro and in vivo (preclinical) - Reduces SASP‑associated inflammatory signaling in senescence models - Improves tissue function and physical performance measures in aged/chemotherapy‑exposed mouse models - Spares proliferating/non‑senescent cells at effective concentrations in preclinical studies - Protease‑resistant D‑retro‑inverso design supports enhanced stability vs L‑peptides ### Quick Stats Typical Dose Model‑dependent; follow published preclinical protocols Frequency Intermittent pulse dosing in many rodent studies Cycle Duration 1–4 weeks in vivo (model‑dependent) Storage Aliquot and store frozen (e.g., −20 to −80°C) desiccated; avoid repeated freeze–thaw cycles ## Molecular Information Molecular Weight ~4–5 kDa (sequence‑dependent) Formula N/A Length ~34 amino acids (D‑retro‑inverso) Type D‑retro‑inverso cell‑penetrating peptide (FOXO4 CR3‑derived) Half-Life Several hours in preclinical models (protease‑resistant D‑peptide) ### Modifications D‑retro‑inverso (all‑D) peptide corresponding to the FOXO4 CR3 region that binds p53 Typically includes a cell‑penetrating segment (e.g., TAT) for intracellular delivery Amide C‑terminus; sequence and exact length can vary by supplier ## Research Indications The following information is derived from published scientific literature and is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. These peptides are not approved for human use and are sold exclusively for in-vitro laboratory research. Cellular senescence models Chemotherapy/chemotoxicity research Aging and degeneration models ## Dosing Protocols ### injectable Employed in preclinical studies via parenteral routes (e.g., intraperitoneal or intravenous) for systemic exposure; cell‑penetrating design supports intracellular delivery. | Goal | Dose | Frequency | Route | | --- | --- | --- | --- | | Senescent cell clearance (rodent) | Dose varies by model; follow study‑specific designs | Intermittent pulse dosing used in several experiments | Parenteral (e.g., IP/IV) | #### Key Tips - Parenteral dosing aligns with published in vivo senolysis studies - Aqueous buffers typically suitable due to cationic sequence composition Reconstitution Instructions ## Peptide Interactions #### p53 pathway modulators (e.g., MDM2 inhibitors such as Nutlin‑3) Monitor Alters p53 availability/localization and may modify FOXO4‑DRI’s pro‑apoptotic effects on senescent cells. #### BCL‑2 family inhibitors (e.g., Navitoclax/ABT‑263) Synergistic Orthogonal senolytic mechanism (intrinsic apoptosis priming) may combine with FOXO4‑DRI for enhanced senescent cell clearance in some models. #### Dasatinib + Quercetin (D+Q) Sequential Common comparator senolytic regimen; may be used in alternating or sequential designs to probe senolytic specificity across cell types. #### mTOR inhibitors (e.g., Rapamycin) Requires Timing mTOR suppression can reduce SASP and senescence burden; timing relative to FOXO4‑DRI may influence readouts. #### DNA‑damaging agents (e.g., Doxorubicin) Monitor Increase senescent cell load in models; FOXO4‑DRI often tested post‑insult to remove senescent cells; co‑administration requires careful timing. #### Antioxidants/NRF2 activators Monitor May modulate oxidative stress and senescence induction, affecting baseline senescent cell burden prior to FOXO4‑DRI treatment. ## What to Expect Hours 0–24 Cellular uptake and engagement of p53; in vitro, early apoptosis markers may emerge in senescent cells within 12–24 h. Days 2–7 Reduction in SA‑β‑gal–positive cells and SASP cytokines in vitro; in vivo, initial biomarker shifts may be detectable. Weeks 1–4 In rodent models, functional improvements (e.g., physical performance, organ function markers) reported following intermittent dosing. >1 month (post‑intervention) Persistence of reduced senescent cell burden and improved tissue markers observed in some studies; durability depends on model and senescence re‑accumulation. ## Side Effects & Safety #### Common Side Effects - Transient malaise or weight changes in some rodent studies (model‑dependent) - Injection‑site irritation (parenteral studies) - On‑target apoptosis of senescent cells with associated transient inflammatory signals during clearance #### Monitoring - Senescence markers: SA‑β‑gal, p16INK4a, p21Cip1, SASP cytokines (IL‑6, IL‑8) - Apoptosis markers in targeted tissues (cleaved caspase‑3, TUNEL) - General toxicity: body weight, CBC/chemistry in animals, histopathology - Functional assays relevant to the model (e.g., grip strength, renal/hepatic panels) #### Stop Signs - Evidence of non‑selective cytotoxicity in non‑senescent cells (e.g., proliferating controls) - Marked organ enzyme elevations or distress in animal models - Unexpected p53 pathway inhibition outside intended senescent cell context #### Contraindications - p53‑null or severely p53‑dysregulated models where mechanism cannot operate as intended - Co‑administration with strong p53 stabilizers without appropriate scheduling - Use outside controlled laboratory/animal research settings ## Quality Checklist #### Good Signs - Verified D‑retro‑inverso configuration and correct length/sequence for the FOXO4 CR3‑derived region - High purity (≥95%) confirmed by HPLC and correct mass by MS - Endotoxin‑controlled for in vivo work - Documentation of counter‑ion/salt form and any CPP used (e.g., TAT) - Stability data (storage conditions, freeze–thaw tolerance) #### Warning Signs - L‑enantiomer or non‑retro‑inverso analogs mislabeled as FOXO4‑DRI - Unclear or undisclosed CPP segment and sequence lengths - Claims of oral bioavailability without data - Lack of identity testing (no MS/HPLC reports) #### Bad Signs - Peptides with incorrect mass/length vs certificate of analysis - Visible particulates or insolubility inconsistent with a cationic CPP‑containing peptide - Supplier cannot provide sequence origin or mechanism description ## Research & References ### Key References 1. 2017 #### Baar et al., Cell: Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging FOXO4‑DRI disrupted FOXO4–p53 interaction, selectively induced apoptosis in senescent cells, and improved function in aged and chemotherapy‑challenged mice. 2. 2017 #### Kirkland & Tchkonia, EBioMedicine: Senolytic drugs and emerging therapeutic strategies for aging and disease Review highlighting senolysis as a strategy; FOXO4‑DRI discussed as a peptide senolytic targeting FOXO4–p53. 3. 2018 #### Review by de Keizer and colleagues on FOXO4–p53 axis in senescence (Trends/Review article) Summarizes the FOXO4–p53 interaction and the rationale for D‑retro‑inverso peptides to target senescent cells; positions FOXO4‑DRI among mechanistically targeted senolytics. [Search PubMed for FOX04-DRI](https://pubmed.ncbi.nlm.nih.gov/?term=%28%22FOX04-DRI%22%20OR%20%22FOXO4%20DRI%22%20OR%20%22FOXO4-DRI%20peptide%22%20OR%20%22FOXO4-DRI%20%28p53-interaction%20inhibitor%29%22%29) --- *Add `.md` to any page URL on peptidesupermarket.co.uk for its Markdown version. Index of the site: https://peptidesupermarket.co.uk/llms.txt - full text: https://peptidesupermarket.co.uk/llms-full.txt.*